Search

Displaying results 2541 - 2550 of 8974 in total
  1. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. … and resolve within 2 to 3 weeks.

  2. Drug

    Idoxuridine

    go.drugbank.com/drugs/DB00249
    ApprovedWithdrawn

    An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]

  4. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

  5. Drug

    Posaconazole

    go.drugbank.com/drugs/DB01263
    ApprovedInvestigationalVet approved

    Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. … [A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although with a reluctance to prescribe it.

  7. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. … [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

    Categories: Receptors, Antigen, T-CellSynonyms: Anti-BCMA CAR T cell
  9. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    It is a synthetic androstane steroid derivative of testosterone in the form of 17β propionate ester of testosterone. … Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]

  10. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018